Horizon Pharma receives additional U.S. patent allowance for Duexis Horizon Pharma announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application Serial No. 13/620,150 entitled "Stable Compositions of Famotidine and Ibuprofen" with claims that cover Duexis tablets. Duexis is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers.
Horizon Pharma files to sell 11.66M shares for existing holders Horizon Pharma announced a proposed underwritten secondary offering of 11.66M of its ordinary shares held by certain of its existing shareholders. Morgan Stanley, Citigroup, Cowen and Jefferies are acting as joint book-running managers for this offering. JMP Securities is acting as financial advisor for this offering.